tiprankstipranks
Trending News
More News >
4DMedical Ltd (AU:4DX)
ASX:4DX
Australian Market

4DMedical Ltd (4DX) AI Stock Analysis

Compare
40 Followers

Top Page

AU

4DMedical Ltd

(Sydney:4DX)

Rating:42Neutral
Price Target:
AU$0.50
▲(66.67%Upside)
4DMedical Ltd is primarily challenged by its financial performance, with strong revenue growth overshadowed by unprofitability and negative cash flows. Technical analysis shows neutral momentum, while valuation is weak due to a negative P/E ratio. The stock needs operational improvements for better investor appeal.

4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)

4DMedical Ltd Business Overview & Revenue Model

Company Description4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
How the Company Makes Money4DMedical Ltd generates revenue primarily through the commercialization of its proprietary imaging technology. The company earns money by selling its XV Technology system to healthcare providers, hospitals, and research institutions. Additionally, 4DMedical may engage in licensing agreements and partnerships, allowing other entities to utilize their technology in exchange for fees or royalties. The company might also offer subscription-based services for ongoing software support, updates, and maintenance of their imaging systems, contributing to a recurring revenue stream. Strategic collaborations with medical institutions and participation in clinical studies may further enhance its revenue potential.

4DMedical Ltd Financial Statement Overview

Summary
4DMedical Ltd demonstrates strong revenue growth, indicative of a promising market position. However, persistent losses, negative margins, and cash flow challenges highlight the need for operational improvements. The balance sheet remains stable but is affected by continuous losses impacting equity returns.
Income Statement
35
Negative
4DMedical Ltd has shown significant revenue growth over the past year, from AUD 282,181 to AUD 3,754,256, indicating a strong upward trajectory in sales. However, the company remains unprofitable, with a negative net profit margin due to substantial losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.
Balance Sheet
40
Negative
The company maintains a healthy equity ratio due to a substantial stockholders' equity base, despite a moderate level of total liabilities. The debt-to-equity ratio is low, showing conservative leverage. However, the continuous net losses adversely impact the return on equity, which remains negative.
Cash Flow
30
Negative
4DMedical Ltd faces challenges with negative operating and free cash flow, reflecting difficulties in generating cash from its core business activities. The free cash flow growth is negative, indicating ongoing cash burn. However, financing cash flow remains positive, supporting liquidity needs.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
5.86M3.75M282.18K1.05M216.98K1.23M
Gross Profit
5.48M3.52M248.03K280.62K125.13K-8.13M
EBIT
-27.46M-27.97M-31.13M-36.75M-18.78M-15.96M
EBITDA
-44.64M-31.86M-33.74M-36.34M-18.04M-15.77M
Net Income Common Stockholders
-39.54M-35.98M-31.46M-24.59M-21.42M-21.98M
Balance SheetCash, Cash Equivalents and Short-Term Investments
15.95M30.61M69.58M51.11M80.88M8.43M
Total Assets
102.01M120.02M92.92M74.31M92.64M15.82M
Total Debt
4.82M5.12M5.14M6.24M1.69M16.49M
Net Debt
-11.13M-25.49M-64.44M-44.88M-79.19M8.06M
Total Liabilities
42.15M49.09M21.46M14.80M9.28M27.63M
Stockholders Equity
59.86M70.93M71.46M59.51M83.36M-11.81M
Cash FlowFree Cash Flow
-30.37M-31.17M-23.38M-28.35M-15.25M-8.81M
Operating Cash Flow
-30.28M-30.87M-22.65M-25.27M-14.52M-7.65M
Investing Cash Flow
-1.52M-40.04M-1.61M-3.50M-580.45K-786.45K
Financing Cash Flow
-127.96K31.94M42.73M-995.47K87.55M13.78M

4DMedical Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.30
Price Trends
50DMA
0.29
Positive
100DMA
0.38
Negative
200DMA
0.43
Negative
Market Momentum
MACD
<0.01
Negative
RSI
49.13
Neutral
STOCH
26.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:4DX, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.30, above the 50-day MA of 0.29, and below the 200-day MA of 0.43, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.13 is Neutral, neither overbought nor oversold. The STOCH value of 26.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:4DX.

4DMedical Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
AU4DX
42
Neutral
AU$139.65M-52.37%471.29%-4.58%
$11.43B46.6220.61%1.61%
$76.28B26.6715.38%1.85%
$850.15M75.429.23%
AURHT
61
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
AURAC
54
Neutral
AU$205.88M-37.20%32.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:4DX
4DMedical Ltd
0.30
-0.36
-54.55%
CHEOF
Cochlear
174.50
-37.32
-17.62%
CMXHF
CSL
162.19
-20.25
-11.10%
NNCSF
Nanosonics Limited
2.72
0.86
46.24%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:RAC
Race Oncology Ltd.
1.18
-0.72
-37.89%

4DMedical Ltd Corporate Events

4DMedical Ltd Announces Quotation of New Securities on ASX
Jun 10, 2025

4DMedical Ltd has announced the quotation of 5,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of an employee incentive scheme, indicating the company’s commitment to rewarding its workforce and potentially enhancing employee engagement and retention.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Expands Lung Health Portfolio with Imbio Acquisition
May 30, 2025

4DMedical Limited has issued nearly 15 million shares as part of the earnout consideration for its acquisition of Imbio Inc. This strategic move is expected to strengthen 4DMedical’s position in the healthcare industry, particularly in the field of lung health, by integrating Imbio’s capabilities and expanding its technological offerings.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Ltd Announces Quotation of New Securities on ASX
May 29, 2025

4DMedical Ltd has announced the quotation of 14,964,623 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX, effective May 29, 2025. This move is part of a previously announced transaction and is expected to bolster the company’s market presence and provide additional capital for its ongoing operations and strategic initiatives.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Limited Releases Investor Presentation
May 27, 2025

4DMedical Limited has released an investor presentation providing a general overview of the company’s current activities and operations as of May 27, 2025. The presentation is informational and not intended as a financial product advice or an offer for securities, emphasizing the company’s commitment to transparency while highlighting legal restrictions on distribution, particularly in the United States.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Files FDA Submission for Revolutionary CT:VQ™ Lung Imaging Software
May 26, 2025

4DMedical Limited has filed an FDA 510(k) submission for its CT:VQ™ software, a groundbreaking non-contrast CT-based lung imaging product that assesses both ventilation and perfusion in the lungs. This innovation addresses clinical and logistical challenges associated with traditional nuclear VQ imaging, offering higher resolution and accessibility by leveraging existing CT infrastructure. The company anticipates capturing the entire market of one million annual nuclear VQ scans in the U.S., with potential global market expansion. CT:VQ™ is expected to drive long-term growth in demand for lung assessments, transforming pulmonary care by making comprehensive evaluations more accessible, even in facilities without nuclear medicine capabilities.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Secures Major Contract with Intermountain Health for PHA™ Product
May 5, 2025

4DMedical Limited has secured a commercial contract with Intermountain Health, a prominent U.S. health system, for its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product. This contract, facilitated through a strategic partnership with Nuance Communications, marks the first major deployment of the PHA™ algorithm in a large health network, enhancing clinical decision-making and potentially expanding 4DMedical’s market presence. The agreement represents a significant opportunity for revenue growth as it transitions to full commercial terms, with plans to increase usage and expand to other products within the health system.

4DMedical’s Top 20 Investors Hold Majority Stake
May 2, 2025

4DMedical Ltd has released its First 20 Investors Report, detailing the top investors holding significant shares in the company. The report reveals that the top 20 investors collectively hold 51.61% of the company’s issued capital, with CITICORP NOMINEES PTY LIMITED leading at 21.15%. This concentration of ownership among a few key investors could impact the company’s strategic decisions and market influence.

4DMedical Ltd Announces New Securities Quotation on ASX
May 2, 2025

4DMedical Ltd has announced the application for quotation of new securities on the ASX, specifically options expiring on February 28, 2026. This move involves issuing listed options to participants of their recent SPP and placement, potentially enhancing the company’s capital structure and market presence.

4DMedical Successfully Passes All Resolutions at Extraordinary General Meeting
May 1, 2025

4DMedical Limited announced that all resolutions proposed at its Extraordinary General Meeting were successfully passed. This outcome supports the company’s strategic initiatives, including the ratification of share issues and the approval of new options, which are expected to strengthen its financial position and operational capabilities. These developments are likely to enhance 4DMedical’s industry positioning and provide further value to its stakeholders.

4DMedical Reports Strong Revenue Growth and Strategic Advancements in Q3 FY2025
Apr 29, 2025

4DMedical Limited reported a significant increase in operating revenue for the year-to-date FY2025, achieving a 103% rise compared to the previous period, with gross margins of 91.4%. The company is expanding its sales pipeline and has secured key contracts, including a renewal with the Cleveland Clinic and conversions of pilot programs into commercial contracts. A cost reduction program has been implemented, resulting in $6.5 million in annualized savings. The company is preparing for the FDA submission of its CT:VQ™ product, which has attracted interest from major medical centers and industry collaborators. Additionally, 4DMedical has received regulatory clearance for its CT LVAS™ in Canada and has been highlighted by Philips as a solution for improving veteran health outcomes.

4DMedical Ltd Announces Quotation of New Securities on ASX
Apr 24, 2025

4DMedical Ltd has announced the quotation of 131,498 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. These securities were issued as part of an employee incentive scheme and are not subject to transfer restrictions, indicating a strategic move to incentivize and retain talent within the company.

4DMedical Simplifies Options Offer Process with Supplementary Prospectus
Apr 16, 2025

4DMedical Limited has lodged a supplementary prospectus with the Australian Securities and Investments Commission, amending the terms of its New Options and Piggyback Options offers. The company has streamlined the application process for eligible participants, who will automatically be deemed to have applied for their allocation unless they choose to opt out. This move aims to simplify participation and potentially increase stakeholder engagement in anticipation of future FDA clearance for its CT:VQ technology.

4DMedical Announces Change of Registry Address in Sydney
Apr 15, 2025

4DMedical Limited has announced a change in the address of its registry office in Sydney, effective from April 14, 2025. This move is part of the company’s ongoing efforts to streamline its operations and maintain compliance with ASX regulations. The change is not expected to impact the company’s operations or its stakeholders significantly, as contact details remain unchanged.

4DMedical Expands Lung Imaging Technology with Integral Diagnostics Contract
Apr 14, 2025

4DMedical Limited has successfully transitioned its pilot program with Integral Diagnostics into a commercial contract, marking a significant expansion of its lung imaging technology across Victoria, Australia. This development will enhance access to 4DMedical’s advanced diagnostic tools for general practitioners, respiratory specialists, and cardiologists, improving patient outcomes through more accurate and timely diagnoses of respiratory conditions. The contract signifies strong demand for 4DMedical’s innovative solutions and reinforces its commitment to revolutionizing lung health, further solidifying its commercial presence in the Australian market.

4DMedical Expands Industry Partnerships and Gains Congressional Recognition
Apr 10, 2025

4DMedical Limited has secured two new contracts to supply its advanced lung imaging technology for clinical trials, one with SMS Biotech for a COPD stem cell therapy trial and another with an unnamed medical device developer. This highlights 4DMedical’s growing role in the respiratory health sector and its strategic partnerships aimed at advancing lung disease treatments. Additionally, 4DMedical’s technology was featured in a US Congressional testimony by Philips, emphasizing its potential to improve veteran healthcare outcomes through enhanced pulmonary diagnostics.

4DMedical Announces Extraordinary General Meeting to Discuss Key Financial Decisions
Mar 31, 2025

4DMedical Limited has announced an Extraordinary General Meeting scheduled for May 1, 2025, in Melbourne, Australia. The meeting will address several business matters, including the ratification of shares issued under a placement and the approval of new options. This meeting is significant for stakeholders as it involves key decisions impacting the company’s financial strategies and shareholder interests.

4DMedical Implements Cost Reduction Program to Enhance Financial Stability
Mar 26, 2025

4DMedical Limited has announced a strategic review resulting in a cost reduction program expected to save $6.5 million annually. This initiative, alongside a successful $13.9 million capital raise, aims to optimize operational efficiency without impacting revenue growth or key milestones. The company is focusing on expanding its commercial activities, particularly in the US, and advancing its CT:VQ™ technology post-FDA clearance. Changes in company leadership include the appointment of Chris Cox as Interim CFO and Hamish George as Company Secretary. These measures are intended to safeguard the company’s long-term growth and financial stability.

4DMedical Ltd Announces New Options Issuance to Boost Market Presence
Mar 25, 2025

4DMedical Ltd has announced a target market determination related to the issuance of new quoted options and piggyback options, which are tied to the company’s shares. These options are part of a prospectus set to be lodged in March 2025, aimed at institutional and sophisticated investors, eligible shareholders, and sub-underwriters. The options are designed to facilitate the trade of shares upon exercise, with the issuance subject to shareholder approval and ASX quotation requirements. This move is expected to enhance the company’s market positioning by potentially increasing share liquidity and attracting more investors.

4DMedical Ltd Announces Strategic Options Offers
Mar 25, 2025

4DMedical Ltd has announced a series of options offers, including SPP Options, Placement Options, Sub-Underwriter Options, and Piggyback Options, aimed at providing shareholders and eligible participants with opportunities to acquire new options. These offers are contingent upon obtaining shareholder approval under ASX Listing Rule 7.1. The initiative is part of the company’s strategic financial maneuvers to enhance its market position and provide value to its stakeholders.

4DMedical Secures $13.9 Million to Boost Lung Diagnostics Commercialization
Mar 25, 2025

4DMedical Limited has successfully completed an oversubscribed Securities Purchase Plan (SPP), raising $8.4 million, which, combined with a previous $5.5 million Placement, totals $13.9 million. These funds will support the company’s efforts to commercialize its lung diagnostics portfolio and advance the FDA submission of its CT:VQ™ technology. The capital raised positions 4DMedical to enhance its market presence and continue developing innovative respiratory diagnostic tools, benefiting shareholders and the broader healthcare industry.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.